)

ALX Oncology Holdings (ALXO) investor relations material
ALX Oncology Holdings Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
CD47 expression identified as a key predictive biomarker for evorpacept response, driving a biomarker-focused strategy in HER2-positive cancers and leading to revised clinical trial designs in both breast and gastric cancer.
Evorpacept demonstrated strong efficacy in HER2-positive gastric and breast cancers, with 65% ORR in CD47-high subgroups and 55.6% ORR in confirmed HER2-positive breast cancer patients.
ALX-2004, a novel EGFR-targeted ADC, is set to enter Phase 1 with first patient dosing in August 2025 and initial safety data expected in 1H 2026.
Cash runway extended into Q1 2027 through pipeline prioritization, cost management, and pausing non-core programs such as colorectal cancer.
Leadership changes include the appointment of Daniel Curran, M.D., to the Board and Allison Dillon, Ph.D., as COO.
Financial highlights
Cash, cash equivalents, and investments totaled $83.5–$84M as of June 30, 2025, with cash runway projected into Q1 2027.
Q2 2025 net loss was $25.9M, down from $39.4M in Q2 2024, driven by reduced R&D and G&A expenses.
Operating expenses for Q2 2025 decreased 36% year-over-year to $26.6M.
No product revenue generated; all funding from equity, debt, and ATM offerings.
$3.2M impairment charge recorded in Q2 2025 related to subleasing lab space.
Outlook and guidance
Cash position expected to fund operations into Q1 2027, supporting key clinical milestones.
ASPEN-Breast patient dosing to begin in Q4 2025; interim data readout anticipated in Q3 2026.
ALX-2004 Phase 1 trial to begin enrollment in August 2025, with initial safety data expected in 1H 2026.
Full ASPEN-6 biomarker data to be presented at a medical conference in Q4 2025.
Additional capital will be needed for full business plan execution.
Next ALX Oncology Holdings earnings date

Next ALX Oncology Holdings earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage